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Introduction
Until recently, anticancer drug development has mainly
involved the screening of libraries of frequently unselected
compounds against tumor cell lines in vitro [1]. Active
agents in this screen were then assessed preclinically
before their assessment in clinical trials. This nonspecific
process proved expensive, lengthy and inefficient, with
paclitaxel taking three decades to progress from bench to
bedside [2]. The earliest exception to this drug develop-
ment paradigm was the successful development of
hormone therapy after the discovery by Sir George
Beatson that mammary carcinomas regressed after bilat-
eral oophorectomy [3]. This led to the use of tamoxifen,
the development of aromatase inhibitors and the selective
estrogen receptor (ER) modulators, which remain arguably
the most successful therapeutics for the treatment of
breast cancer. Another exception was the successful
development of the monoclonal antibody trastuzumab
(Herceptin) [4]. This followed the identification of erbB2
(HER2) amplification in a subgroup of breast cancers and
the recognition that erbB2 signaling has an important role
in driving the proliferation of this variant of the disease
These rationally designed and target-based agents are
characterized by low toxicity, clinical efficacy and wide
therapeutic indices. This is due to their ability to induce
selective tumor cell cytotoxicity, inducing disease regres-
sion in cancers by targeting aberrations that contribute to
the tumor’s proliferative advantage, while sparing normal
tissue. Preferential cytotoxicity against malignant tissues
remains tantamount to the Holy Grail in oncologic thera-
peutics because it portends improved patient tolerance
and overall quality of life. This would result in selective
killing of tumor cells, affecting the equilibrium between
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Abstract
Although mortality from breast cancer is decreasing, 15% or more of all patients ultimately develop
incurable metastatic disease. It is hoped that new classes of target-based cytotoxic therapeutics will
significantly improve the outcome for these patients. Many of these novel agents have displayed
cytotoxic activity in preclinical and clinical evaluations, with little toxicity. Such preferential cytotoxicity
against malignant tissues will remain tantamount to the Holy Grail in oncologic therapeutics because
this portends improved patient tolerance and overall quality of life, and the capacity to deliver
combination therapy. Combinations of such rationally designed target-based therapies are likely to be
increasingly important in treating patients with breast carcinoma. The anticancer efficacy of these
agents will, however, remain dependent on the involvement of the targets of these agents in the biology
of the individual patient’s disease. Results of DNA microarray analyses have raised high hopes that the
analyses of RNA expression levels can successfully predict patient prognosis, and indicate that the
ability to rapidly ‘fingerprint’ the oncogenic profile of a patient’s tumor is now possible. It is hoped that
these studies will support the identification of the molecules driving a tumor’s growth, and the selection
of the appropriate combination of targeted agents in the near future.
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tumor cell proliferation and cell death and leading to
disease regression, the patient’s symptomatic improve-
ment, and a survival advantage, while sparing normal
tissues and inducing minimal toxicity. It also allows more
‘breathing room’ or capacity to develop combinations of
these agents. This is critically important: effective anti-
cancer treatment is likely to involve combinations of multi-
ple agents because carcinogenesis is a multi-step
process involving several genes and pathways [5]. The
primary thesis of this commentary is that the future of cyto-
toxic anticancer therapy lies with the development of
biology-based combinations of molecularly targeted
agents that can induce selective tumor cell death.
Non-toxic target-based cytotoxics
The successful development of these selectively cytotoxic,
rationally targeted, antitumor agents resulted directly from
observations demonstrating the critical biological rele-
vance of ER and erbB2 in subgroups of breast cancers.
The development of similar anticancer therapeutics tar-
geted to specific oncogenic molecules is becoming the
norm, with drug discovery efforts being increasingly
focused on such therapies. This has accelerated the pre-
clinical discovery of target-based compounds with demon-
strable activity against their target, and has rapidly
increased the number of antitumor agents in clinical devel-
opment. These include monoclonal antibodies, small mole-
cules, and synthetic nucleic acid sequence-based
approaches targeting a variety of pathways associated
with cancer (see Table 1).
A large, and rapidly increasing, number of potential molec-
ular targets have been described. Mechanisms being
exploited by these agents include the modulation of cellu-
lar signaling, programmed cell death, the cell cycle, and
angiogenesis. Although the specific roles of many of these
potential molecular targets in driving tumor growth in
breast cancers remains frequently unknown, drugs target-
ing an increasingly large number of putative oncoproteins
are now available for clinical evaluation. The attraction of
developing agents against these targets is the potential to
induce selective tumor cytotoxicity, sparing normal tissues
and therefore resulting in little toxicity, with their success
being largely dependent on the magnitude of this speci-
ficity. Agents targeting for example the signaling proteins
erbB1, Ras, Raf, MAP kinase/ERK kinase (MEK), Akt,
mTOR (mammalian target of rapamycin), the nuclear factor
NF-κB, apoptotic transducers such as bcl-2 and TRAIL,
and angiogenic factors such as vascular endothelial
growth factor (VEGF) are currently being evaluated
(Fig.1). Promising tolerability has already been demon-
strated in many early clinical trials with agents targeting
the erbB receptors, Ras, Raf, MEK, mTOR, bcl-2, and
both VEGF and its receptor (VEGFR) signaling; many of
these studies have confirmed effective clinical target
blockade [6–16].
Optimal efficacy requires drug combinations
Our clinical expectations with these targeted compounds
remain similar to those associated with the development
Table 1
Targeted therapies in clinical development
Target Agent Agent class
EGFR IMC-C225 Cetuximab, Monoclonal antibody
Erbitux (Imclone)
ABX-EGF (Abgenix) Monoclonal antibody
EMD 72000 Monoclonal antibody
(Merck KgaA Darmstadt)
ZD 1839 gefitinib, Small molecule kinase
Iressa (AstraZeneca) inhibitor
OSI-774, erlotinib, Tarceva Small molecule kinase
(OSI-Pharmaceuticals) inhibitor
CI-1033/PD183805 (Pfizer) Small molecule kinase
inhibitor
EKB-569 (Wyeth Ayerst) Small molecule kinase
inhibitor
GW2016/572016 Small molecule kinase
(GlaxoSmithKline) inhibitor
HER2/neu Trastuzumab, Herceptin Monoclonal antibody
(Genentech)
2C4 (Genentech) Monoclonal antibody
17-AAG Geldanamycin derivative
inhibits HSP90
TAK-165 Small molecule inhibitor
(Takeda Pharmaceuticals)
GW2016/572016 Small molecule kinase
(GlaxoSmithKline) inhibitor
CP 724, 714 (Pfizer) Small molecule inhibitor
Ras R115777 Farnesyl  transferase
(Johnson and Johnson) inhibitor
SCH66336 (Schering-Plough) Farnesyl transferase
inhibitor
BMS214662 Farnesyl transferase
(Bristol Myers Squibb) inhibitor
CT-2584HMS Farnesyl transferase
(Cell Therapeutics) inhibitor
Raf BAY 43-9006 (Onyx/Bayer) Small molecule kinase
inhibitor
MEK PD 184352/CI-1040 (Pfizer) Small molecule kinase
inhibitor
PKC-α ISIS 3521/LY900003 Affinitak Antisense
(ISIS Pharmaceuticals) oligonucleotide
CGP41251/PKC412 (Novartis) Staurosporine analogue
Bryostatin-1 Small molecule kinase
inhibitor
UCN-01 (Kyowa Hakko Kogyo) Staurosporine analogue
PKC-β LY333531 (Eli Lilly) Small molecule kinase
inhibitor
Akt 17-AAG Inhibitor of HSP90
Perifosine (Zenataris) Alkylphospholipid
mTOR CCI-779 (Wyeth) Inhibits mTOR kinase by
binding to FKBP
RAD001 (Novartis) Inhibits mTOR kinase by
binding to FKBP
EGFR, epidermal growth factor receptor; MEK, MAP kinase/ERK
kinase; mTOR, mammalian target of rapamycin; PKC, protein kinase C.156
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of nonspecific therapeutics. These relevant therapeutic
endpoints include increasing overall survival, regressing
tumor lesions in association with clinical benefit, and/or
palliating disease-related symptoms [17]. However, it is
likely that the clinical benefit from these agents used indi-
vidually as single agents will be of low magnitude because
most cancers have multiple defects driving tumor cell
growth. This has in fact already been observed in efficacy
studies with many targeted agents. Low-level response
rates in patients with unselected metastatic breast carci-
noma have been documented with agents targeting erbB1
(ZD1839; Astra-Zeneca Pharmaceuticals), Ras
(R115,777; Johnson and Johnson Pharmaceuticals),
mTOR (CCI-779; Wyeth Pharmaceuticals) and VEGF
(bevacizumab; Genentech) [8,13,16,18]. Nevertheless,
the low incidence of severe nonspecific toxic effects of
these agents enhances their overall appeal and supports a
rationale for preferentially focusing on the development of
these agents. However, it is likely that maximal benefit
from these agents will not be attained until they are used
in combinations that can, overall, reverse the malignant
drive of the tumor cell.
Realistic expectations from early clinical trials with these
agents, based on an understanding of cancer biology, are
required to avoid the rejection of valuable agents due to
perceived inefficacy in single-agent efficacy trials. To maxi-
mize the clinical benefit from these agents they will need
to be administered in combination to patients with tumors
with the appropriate molecular signatures. For example,
preclinical data indicate that trastuzumab resistance in
erbB2-positive breast carcinoma might be due in part to
signaling by the insulin growth factor-I receptor [19].
Blockade of downstream receptor signaling by, for
example, a farnesyltransferase inhibitor might therefore
potentiate the anticancer activity of trastuzumab (see
Fig.1). Combination therapy with trastuzumab and the far-
nesyltransferase inhibitor R115,777 is being investigated
in the clinic; initial clinical studies indicate that full doses
of both agents can be concurrently administered in the
clinic with minimal toxicity [20]. Growth factor signaling
has also been demonstrated to have a role in the develop-
ment of endocrine-resistant breast carcinoma. Preclinical
studies suggest that growth factor receptor signaling can
activate the estrogen receptor in the absence of estrogen
ligand, thereby mediating hormone resistance (Fig.2)
[21–23]. It has therefore been postulated that growth
factor signaling blockade might enhance the antitumor
activity of hormone therapy, and could potentially reverse
hormone resistance in patients with estrogen-receptor-
positive disease. Combination studies with erbB receptor
tyrosine kinase inhibitors are therefore being pursued,
including Phase II studies of ZD1839 and anastrazole, and
GW572016 and letrozole, in patients that have previously
failed aromatase inhibition. Preclinical data also support
combination clinical studies of hormonal agents and
Figure 1
Clinical trials evaluating combinations of trastuzumab and other signal transduction inhibitors targeting erbB growth factor receptor tyrosine kinases
(for example OSI-774, ZD-1839, GW572016, CI-1033) or downstream kinases (R115,777, BAY 43-9006, CI-1040) are needed to enhance the
anticancer activity of trastuzumab and reverse trastuzumab resistance in HER2-positive disease. Erk, extracellular signal-regulated protein kinase;
MEKK, MAP kinase/Erk kinase kinase; PI3-kinase, phosphoinositide 3-kinase.157
downstream signaling inhibitors such as the farnesyltrans-
ferase inhibitors or the mTOR inhibitors in treatment-naïve,
estrogen-receptor-positive, disease. These preclinical
studies indicate that cytoplasmic estrogen receptor acti-
vates Shc directly, generating Shc–Grb2–Sos complex
formation and downstream signaling through activated Src
and Ras (see Fig.2) [24]. Clinical data from these combi-
nation studies are likely to become available in the very
near future.
Optimal efficacy requires patient selection
Inherent in the development of target-based therapeutics
is also the notion that this anticancer activity may be maxi-
mized by selectively treating patients whose tumors are
particularly driven by the target aberration and would
therefore be expected to respond most profoundly. This
can be achieved by screening tumors for the relevant
target, or targets, and either structural or functional deter-
minants that can predict antitumor activity. For
trastuzumab, the study of tumor cell HER2 gene amplifica-
tion, based on screening by fluorescence in situ hybridiza-
tion (FISH) or immunohistochemistry, allows the selection
of the patients most likely to benefit from therapy [25]. For
other rationally designed target-based therapeutics such
as the erbB1 inhibitors, the farnesyltransferase inhibitors,
and the mTOR kinase inhibitors, similar screening test
determinants predicting anticancer activity, thereby allow-
ing patient selection, have not yet been refined. It is envis-
aged, for these inhibitors of kinase signaling, that immuno-
histochemical studies of tumor tissue, perhaps using
phosphorylation-specific antibodies for the respective sig-
naling targets, might allow the oncologist to select the
optimal rationally designed targeted agent for the individ-
ual patient. For example, studies are needed to evaluate
whether screening for phosphorylated tumor-cell Akt
expression could portend benefit from mTOR inhibitors
such as CCI-779 [12].
Although these simple screening approaches could opti-
mize the clinical benefits imparted from a single agent, a
more comprehensive understanding of the critically impor-
tant differences between breast cancer cells and normal
cells may be essential to affect patient outcome substan-
tially. In particular, understanding target function, and the
impact of target blockade, in the overall molecular frame-
work of normal and cancer cells, may be crucial in select-
ing the most clinically relevant molecular targets for the
individual patient.
Target selection must be based on tumor
biology
Overall, it is envisaged that the future successful develop-
ment of these target-based cytotoxic agents will depend
on a detailed understanding of breast cancer biology.
Available online http://breast-cancer-research.com/content/5/3/154
Figure 2
Estrogen receptor-α (ERα) can be directly activated, by serine phosphorylation at Ser-118 and Ser-167, by mitogen-activated protein kinase
(MAPK) and Akt respectively, through growth factor signaling. This can result in the ligandless activation of ERα and hormone resistance. Clinical
trials of combinations of signaling inhibitors and hormonal agents are needed to investigate whether signaling blockade can enhance hormone
resistance.158
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These target-based drugs might not achieve their full ther-
apeutic potential until the oncogenic role of their targets,
in the biology of a specific variant of breast cancer, is
ascertained. The dissection of the biology of breast
cancer remains a major challenge, particularly because of
the considerable interpatient and intrapatient molecular
heterogeneity in tumor cells. Nevertheless, major inroads
into precise molecular profiling of this disease using DNA
microarrays are being rapidly made through the study of
the entire set of genes expressed in these tumor cells.
These studies indicate that gene expression signatures
can distinguish between good prognosis and poor prog-
nosis patients through the analyses of a small subset of
70 predictor genes, with the majority of genes not influ-
encing clinical outcome [26,27].
These encouraging results have identified that a small
number of genes regulating the cell cycle, invasion, meta-
stasis, and angiogenesis predict poor clinical outcome.
They raise high hopes that the analyses of RNA expression
levels by DNA microarray can successfully predict patient
prognosis, and suggest that the ability to rapidly ‘finger-
print’ the oncogenic profile of a patient’s tumor might soon
become reality. It is probable that these studies will support
the identification of the molecular aberrations contributing
to the tumor’s proliferative advantage, and the selection of
the appropriate combination of targeted agents in the near
future. This would then direct the future successful clinical
application of the rapidly increasing numbers of targeted
therapeutics being developed.
Conclusion
It is hoped that the development of target-based therapeu-
tics, coupled with an increased understanding of tumor
biology, will allow the delivery of tailored and highly effica-
cious tolerable combinations of these agents. These com-
binations, selected for the individual patient through the
molecular profiling of the individual tumor, might then be
able to maximize tumor cell kill, tumor regression, and
patient benefit. The earlier evaluation of combinations of
well-tolerated target-based compounds that have not
demonstrated sufficient anticancer efficacy as single
agents to warrant regulatory approval must be encour-
aged. This will help to ensure that potentially valuable
agents are not discarded because of the inefficacy of a
single agent, when these agents could impart clinically
significant benefit when used in combination.
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